NEW YORK, NY / ACCESSWIRE / October 12, 2017 / All three major indexes closed at record highs Wednesday after minutes from the most recent Federal Reserve Meeting suggested a December rate hike was not certain. The Dow Jones Industrial Average gained 0.18 percent to close at a record 22,872.89, while the S&P 500 Index increased 0.18 percent to close at a record 2,555.24. The NASDAQ Composite Index rose 0.25 percent to close at a record 6,603.55.
"What is telling about these minutes is the growing rift among Fed officials and the notion that a December hike is anything but guaranteed. We do know the Fed has a rate destination in mind, and a stated goal of three this year, but it still may be too early to tell if it will be this year or next," said Mike Loewengart, Vice President of investment strategy at E*Trade, according to MarketWatch.
RDI Initiates Coverage on:
Pluristem Therapeutics Inc.
Athersys Inc.'s stock jumped 7.17% Wednesday, to close the day at $2.39. The stock recorded a trading volume of 4,815,022 shares, which was above its three months average volume of 1,025,130 shares. In the last year, Athersys Inc.'s shares have traded in a range of 1.02 - 2.63. The share price has gained 134.31% from its 52 week low. The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $2.10 is greater than its 200-day moving average of $1.67. Shares of Athersys have gained approximately 56.21 percent year-to-date.
Access RDI's Athersys Inc. Research Report at:
On Wednesday, shares of Pluristem Therapeutics Inc. recorded a trading volume of 3,866,504 shares, which was above the three months average volume of 389,562 shares. The stock ended the day 15.24% higher at 1.89. The share price has gained 81.73% from its 52 week low with a 52 week trading range of 1.04 - 2.02.The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $1.36 is greater than its 200-day moving average of $1.32. Shares of Pluristem Therapeutics have gained approximately 32.17 percent year-to-date.
Access RDI's Pluristem Therapeutics Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.